Quest Diagnostics Incorporated (NYSE:DGX) Q3 2024 Earnings Conference Call October 22, 2023 8:30 AM ET

Company Participants

Jim Davis - President, Chief Executive Officer
Sam Samad - Executive Vice President, Chief Financial Officer
Shawn Bevec - Vice President, Investor Relations

Conference Call Participants

Ann Hynes - Mizuho Securities
Michael Cherny - Leerink Partners
Patrick Donnelly - Citi
Pito Chickering - Deutsche Bank
Meghan Holtz - Jefferies
David Westenberg - Piper Sandler
Jack Meehan - Nephron Research
Elizabeth Anderson - Evercore ISI
Erin Wright - Morgan Stanley
Stephanie Davis - Barclays
Lisa Gill - JP Morgan
Andrew Brackmann - William Blair
Kevin Caliendo - UBS
Michael Riskin - Bank of America

Operator

Welcome to the Quest Diagnostics Third Quarter 2024 conference call. At the request of the company, this call is being recorded. The entire contents of the call, including the presentation and the question and answer session that will follow, are copyrighted property of Quest Diagnostics with all rights reserved. Any redistribution, retransmission or rebroadcast of this call in any form without the written consent of Quest Diagnostics is strictly prohibited.

I’d now like to turn the call over to Shawn Bevec, Vice President of Investor Relations for Quest Diagnostics. Sir, please go ahead.

Shawn Bevec

Thank you and good morning. I’m joined by Jim Davis, our Chairman, Chief Executive Officer and President, and Sam Samad, our Chief Financial Officer.

During this call, we may make forward-looking statements and will discuss non-GAAP measures. We provide a reconciliation of non-GAAP measures to comparable GAAP measures in the tables to our earnings press release. Actual results may differ materially from those projected. Risks and uncertainties that may affect Quest Diagnostics’ future results include but are not limited to those described in our most recent annual report on Form 10-K and subsequently filed quarterly reports on Form 10-Q and current reports on Form 8-K.

For this call, references to reported EPS refer to reported diluted EPS, and references to adjusted EPS refer to adjusted diluted EPS. Growth rates associated with our long term outlook projections, including consolidated revenue growth, revenue growth from acquisitions, organic revenue growth, and adjusted earnings growth are compound annual growth rates.

Now here is Jim Davis.

Jim Davis

Thanks Shawn, and good morning everyone.

Before we get into the details from the third quarter, I want to recognize the Quest employees who are working hard to serve our patients and customers impacted by Hurricanes Helene and Milton while also contending with the effects on their personal lives. I’m inspired by their commitment to our values, especially customer focus, collaboration and care during this very difficult time. They bring to life our purpose - working together to create a healthier world one life at a time.